Nitin Vaishampayan

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Cognitive Impairment in Musculoskeletal Pain Patients

Donald G. Kewman, Nitin Vaishampayan, David H. Zald et al. · The International Journal of Psychiatry in Medicine · 1991 · 167 citations

Medicine, Neurology, Rehabilitation Medicine +17

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

Michael J. Morris, Johann S. de Bono, Kim N. et al. · Journal of Clinical Oncology · 2021 · 74 citations

Medicine, Oncology, Pharmacology +17

Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT)

Hamilton Trinh, Stephen P. Dzul, Jalal Hyder et al. · Clinica Chimica Acta · 2020 · 71 citations

Medicine, Oncology, Radiation Oncology +15

[¹⁷⁷Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.

Nitin Vaishampayan, Michael J. Morris, Bernd J. Krause et al. · Journal of Clinical Oncology · 2022 · 25 citations

Medicine, Nuclear Medicine, Pharmacology +17